Dishman Carbogen Amcis Fair Value
Dishman Carbogen Amcis (DCAL) average fair value is ₹1277.99 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹195.37 (+554.14%), fair value range ₹74.45–₹4900.77. See DCAL book value comparison to compare market price against book value per share.
Fair Value Analysis Export
DCAL Fair Value vs Current Price — Valuation Summary
DCAL average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Examine DCAL earnings for recent quarterly revenue, profit and EPS trends.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
DCAL Fair Value Analysis — Data Sources & Coverage
Dishman Carbogen Amcis financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit Dishman Carbogen Amcis stock price NSE.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
DCAL vs Healthcare Sector Peers — P/E, P/B & Market Cap
Dishman Carbogen Amcis P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Auro Laboratories | AUROLAB | 90.85 | 3.89 | ₹167 |
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.